Vaccination of hormone‐refractory prostate cancer patients with peptide cocktail‐loaded dendritic cells: Results of a phase I clinical trial
The Prostate2006Vol. 66(8), pp. 811–821
Citations Over TimeTop 10% of 2006 papers
Susanne Fuessel, Axel Meye, Marc Schmitz, Stefan Zastrow, C. Linné, K. Richter, B. Löbel, Oliver W. Hakenberg, Kristina Hoelig, E. Peter Rieber, Manfred P. Wirth
Abstract
The described protocol represents a safe and feasible concept for the induction of clinical and immunological responses. The application of a peptide cocktail-derived from different antigens as a novel treatment modality is supposed to allow for the genetic and biologic heterogeneity of PCa.
Related Papers
- → Phase II Clinical Trial of Multiple Peptide Vaccination for Advanced Head and Neck Cancer Patients Revealed Induction of Immune Responses and Improved OS(2014)151 cited
- → Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay(2002)63 cited
- → Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy(2007)22 cited
- → Molecular Stating of Prostate Cancer. II. A Comparison of the Application of an Enhanced Reverse Transcriptase Polymerase Chain Reaction Assay for Prostate Specific Antigen Versus Prostate Specific Membrane Antigen(1995)1 cited
- Experimental study of HER2/neu chiral polypeptide vaccine of breast cancer(2008)